Ovid Therapeutics
OVID
103 hedge funds and large institutions have $233M invested in Ovid Therapeutics in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 10 closing their positions.
200% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 10
132% more capital invested
Capital invested by funds: $101M → $233M (+$133M)
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
32.21% more ownership
Funds ownership: 47.46% → 79.67% (+32%)
23% more funds holding
Funds holding: 84 → 103 (+19)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less call options, than puts
Call options by funds: $341K | Put options by funds: $411K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$19.2M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$10.1M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.31M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$6.23M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.99M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.01M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.47M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$769K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$698K |
OVID Hedge Fund Activity: Q1 2026 in Review
103 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2026, worth a combined $233M — up 132% from $101M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new OVID positions and 10 closed out — a net gain of 20 holders — while 33 added to existing stakes and 20 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $19.2M. The largest seller was Point72 Asset Management, cutting an estimated $3.99M.
- 103 institutional investors held Ovid Therapeutics (OVID) as of Q1 2026, up from 84 in Q4 2025.
- Funds reported $233M of Ovid Therapeutics stock for Q1 2026, up 132% quarter-over-quarter.
- 30 funds opened new Ovid Therapeutics positions in Q1 2026 and 10 closed out, a net change of +20 holders.
- The largest Ovid Therapeutics buyer in Q1 2026 was Janus Henderson Group, an estimated $19.2M added.
- The largest Ovid Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $3.99M sold.
Based on aggregated 13F filings for Q1 2026.